Clinical trials: Oncologic Disease
Anemia, Blood Loss, Surgical
An Observational Study of Blood Management Techniques in Oncology Surgical Treatment
The purpose of this study is to observe the methods used to manage blood loss in surgical procedures to remove tumors from patients with cancer and to determine if there is a relationship with the need for blood transfusions.
- Conditions
- Anemia, Blood Loss, Surgical, Neoplasms
- Trial name
- NCT00264095
- Testing
- Oncological surgery
- Where
- 11 sites in Netherlands
- Volunteers
- 488 people
- Sponsor
- Janssen-Cilag B.V.
Myelofibrosis, Leukemia, Myelocytic, Acute
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Phase 1 Part: This was an open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients who had previously been treated for Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms.
- Conditions
- Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02158858
- Testing
- Pelabresib, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 336 people
- Sponsor
- Constellation Pharmaceuticals
Leukaemia, Myelocytic, Acute
A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)
This study is a phase I, open-label study to determine recommended phase 2 dose (RP2D) and regimen for the orally administered lysine specific demethylase 1 (LSD1) inhibitor GSK2879552, alone or in combination with All-Trans…
- Trial name
- NCT02177812
- Testing
- GSK2879552, ATRA
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Locally Recurrent and Metastatic Breast Cancer
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer
This open-label, dose-finding, multi-center study is designed to determine the safety and the maximum tolerated dose of AMG 706 given once daily in combination with either weekly paclitaxel (Arm A) or once-every-3 week docetaxel…
- Trial name
- NCT00322400
- Testing
- Docetaxel, Paclitaxel, AMG 706
- Volunteers
- 46 people
- Sponsor
- Amgen
Ovarian Cancer, Ovarian Neoplasms
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pegylated liposomal doxorubicin (PLD), a type of chemotherapy, is a standard treatment option for patients with platinum-resistant ovarian cancer.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT05261490
- Testing
- maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD)
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT02572687
- Testing
- Ramucirumab, MEDI4736
- Where
- 28 sites in United States, France and 6 more
- Volunteers
- 85 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer, Neoplasm Metastasis
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Multicenter study in which patients with metastatic hormone refractory prostate cancer (HRPC), who have not had previous chemotherapy or immunotherapy treatments, received MDX-010 every 3 weeks for 4 doses (12 weeks total…
- Trial name
- NCT00323882
- Testing
- MDX-010
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma, Advanced Cancer
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT03582618
- Testing
- Sorafenib, CVM-1118
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- TaiRx, Inc.
Neoplasms
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
This trial will evaluate safety and tolerability of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with non-small cell lung cancer.
- Trial name
- NCT03709706
- Testing
- Lete-cel, Pembrolizumab
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Nasopharyngeal Carcinoma
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a multicenter, single-arm open-label, phase II study to evaluate the anti-tumor activity, safety, PK and immunogenicity of AK105 (Anti-PD1 antibody) in patients with metastatic nasopharyngeal carcinoma who have progressed…
- Trial name
- NCT03866967
- Testing
- AK105
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- Akeso
Stomatitis
Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
CG53135-05, a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis.
- Trial name
- NCT00104065
- Testing
- CG53135-05, velafermin
- Where
- 9 sites in United States
- Sponsor
- CuraGen Corporation
Malignant Neoplasm of Breast
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
This study will look at the effect on the QTc interval and pharmacokinetics after multiple dosing in subjects with HER2-expressing metastatic and/or unresectable breast cancer.
- Trial name
- NCT03366428
- Testing
- DS-8201a
- Where
- 7 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Melanoma
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
The purpose of this early (phase I/II) clinical trial is to assess the effects (both good and bad) of genetically modified T cells after chemotherapy on your cancer and general health.
- Trial name
- NCT01350401
- Testing
- Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Adaptimmune
Nasopharyngeal Carcinoma
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a single-arm, open-label, multicenter, phase II study to evaluate the anti-tumor activity, PK and immunogenicity of AK104 in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior…
- Trial name
- NCT04220307
- Testing
- AK104
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Akeso
Gastric Cancer, Gastric Adenocarcinoma
A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC).
- Trial name
- ANGEL (NCT03042611)
- Testing
- Rivoceranib
- Where
- 95 sites in United States, France and 10 more
- Volunteers
- 460 people
- Sponsor
- Elevar Therapeutics
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Breast Cancer
TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.
This is a retrospective, observational study that will document the treatment and monitoring patterns and clinical outcomes of patients diagnosed with HR+/HER2- a/mBC who received Palbociclib combination therapy with aromatase…
- Trial name
- NCT04498481
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Neutropenia
FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
The purpose of the study is to assess the impact of first and subsequent cycle pegfilgrastim on neutropenia events (such as hospitalizations, dose reductions and delays) in patients receiving myelosuppressive chemotherapy.
- Trial name
- NCT00125723
- Testing
- PI Discretion
- Volunteers
- 2,252 people
- Sponsor
- Amgen
Multiple Myeloma, Multiple Myeloma Without Mention of Remission
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing…
- Trial name
- NCT06149910
- Testing
- Multiple Myeloma Pathway, All4Cure Platform, Documentation Pathway
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- All4Cure
Advanced Clear Cell Renal Cell Carcinoma
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell…
- Trial name
- eVOLVE-RCC02 (NCT07000149)
- Testing
- Volrustomig, Casdatifan
- Where
- 3 sites in Australia, South Korea
- Volunteers
- 9 people
- Sponsor
- AstraZeneca